Evidence map›Paper›PMID 41816574›Full record

ArticleJournal of gastrointestinal oncology2026

Shuya Jiang, Dongyang Ding, Yunxi Zu, Yan Liao, Tengjiao Wang, Jian Yu, Weiping Zhou, Shengxian Yuan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shuya Jiang *The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Dongyang Ding *The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Yunxi Zu *The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Yan Liao *Naval Medical University, Shanghai, China.
Tengjiao WangDepartment of Precision Medicine, Translational Medicine Research Center, Naval Medical University, Shanghai, China.
Jian YuDepartment of General Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Weiping ZhouThe Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Shengxian YuanThe Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The role of 2'-O-methyltransferases in hepatocellular carcinoma (HCC) progression, particularly concerning inflammation, remains unclear. This study investigated their prognostic significance, identified key prognostic target Methods: Transcriptomic data from The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA-LIHC) were integrated to data of subtype HCC patients via consensus clustering based on 2'-O-methyltransferase expression. Single-gene survival analysis linked Results: Consensus clustering defined three subtypes. Subtype 1 (high 2'-O-methyltransferase expression) showed the worst prognosis. Conclusions: High 2'-O-methyltransferase abundance predicts poor HCC prognosis.

Indexed as

FTSJ1hepatocellular carcinoma (HCC)inflammatory microenvironmentinterleukin 1 receptor antagonist (IL1RN)messenger RNA destabilization (mRNA destabilization)

Identifiers

PMID41816574
PMCPMC12972008

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.